Covered recipient · General Payments record
JONATHAN MOWREY
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2020–2024
$514.20
- Reported across 15 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $184.65 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $54.82 | 3 |
| ANI Pharmaceuticals, Inc. | $27.31 | 1 |
| Otsuka America Pharmaceutical, Inc. | $26.78 | 1 |
| Mozarc Medical US LLC | $20.39 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $20.35 | 1 |
| AKEBIA THERAPEUTICS INC | $19.27 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $19.27 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145823948 | CMS |
| ANI Pharmaceuticals, Inc. | $27.31 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091164178 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.73 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118100840 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $20.35 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141519901 | CMS |
| Mozarc Medical US LLC | $20.39 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141013541 | CMS |
| Novo Nordisk Inc | $20.40 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097558356 | CMS |
| Novo Nordisk Inc | $15.49 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097815864 | CMS |
| Novo Nordisk Inc | $18.93 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097110815 | CMS |
| Otsuka America Pharmaceutical, Inc. | $26.78 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118946693 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.